Skip to main content
Journal cover image

Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.

Publication ,  Journal Article
Douglas, E; Levine, B; Ansari, A; Ansley, K; Melin, S; Park, CJ; Richardson, K; Hatcher, S; D'Agostino, RB; Jordan, JH; Thomas, A
Published in: Clin Breast Cancer
June 2024

INTRODUCTION: Premenopausal women with high-risk hormone receptor (HR)-positive breast cancer often receive ovarian function suppression (OFS) and anti-estrogen therapy which induces near complete estrogen deprivation (NCED). This treatment improves recurrence-free survival but may increase cardiovascular risk. We sought to identify patterns of cardiovascular care and outcomes in premenopausal women with operable breast cancer. METHODS: Premenopausal women ≤ 50 years of age with stage I-III HR-positive or triple negative breast cancer (TNBC) were identified by retrospective review. We categorized women into 3 groups based on anti-estrogen therapy approach: NCED (HR + OFS), anti-estrogen therapy without OFS (HRnoOFS), and no anti-estrogen therapy (TNBC). Baseline characteristics, post-diagnosis cardiovascular events and cardiovascular actions (tests, referrals and medications) were recorded. Categorical variables were compared among the groups using chi-square and Fisher's exact tests; continuous outcomes were compared using ANOVA. RESULTS: 82, 83, and 52 women were identified in the HR + OFS, HRnoOFS, and TNBC groups respectively; mean follow-up was 5.0 years. Mean number of cardiovascular actions per year were highest in the HR + OFS group compared with HRnoOFS and TNBC groups (0.35 vs. 0.20 and 0.27, respectively; P = .036). The HR + OFS group had significantly more referrals and tests per year than the other groups. Cardiovascular medication initiation did not differ among groups. CONCLUSIONS: In this early follow-up period, there were meaningful numbers of cardiovascular actions, with women on NCED experiencing the most per year. Future work should seek to further understand the impact of anti-estrogen therapy on the cardiovascular health of premenopausal women and test strategies to mitigate cardiotoxicity.

Duke Scholars

Published In

Clin Breast Cancer

DOI

EISSN

1938-0666

Publication Date

June 2024

Volume

24

Issue

4

Start / End Page

e289 / e296

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Retrospective Studies
  • Referral and Consultation
  • Receptors, Estrogen
  • Premenopause
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Douglas, E., Levine, B., Ansari, A., Ansley, K., Melin, S., Park, C. J., … Thomas, A. (2024). Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer. Clin Breast Cancer, 24(4), e289–e296. https://doi.org/10.1016/j.clbc.2024.02.006
Douglas, Emily, Beverly Levine, Ahmer Ansari, Katherine Ansley, Susan Melin, Carolyn J. Park, Karl Richardson, et al. “Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.Clin Breast Cancer 24, no. 4 (June 2024): e289–96. https://doi.org/10.1016/j.clbc.2024.02.006.
Douglas E, Levine B, Ansari A, Ansley K, Melin S, Park CJ, et al. Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer. Clin Breast Cancer. 2024 Jun;24(4):e289–96.
Douglas, Emily, et al. “Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer.Clin Breast Cancer, vol. 24, no. 4, June 2024, pp. e289–96. Pubmed, doi:10.1016/j.clbc.2024.02.006.
Douglas E, Levine B, Ansari A, Ansley K, Melin S, Park CJ, Richardson K, Hatcher S, D’Agostino RB, Jordan JH, Thomas A. Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer. Clin Breast Cancer. 2024 Jun;24(4):e289–e296.
Journal cover image

Published In

Clin Breast Cancer

DOI

EISSN

1938-0666

Publication Date

June 2024

Volume

24

Issue

4

Start / End Page

e289 / e296

Location

United States

Related Subject Headings

  • Triple Negative Breast Neoplasms
  • Retrospective Studies
  • Referral and Consultation
  • Receptors, Estrogen
  • Premenopause
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female